SCHEMBL3136519

SCHEMBL3136519

C=CCNC(=O)CNC(=O)c1cc(O)ccc1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
KDM4E B2RXH2 1/20 0.49
GAA P10253 1/20 0.49
ALOX15 P16050 1/20 0.42
HPGD P15428 5/20 0.42
CYP1A2 P05177 2/20 0.42
POLB P06746 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
MAPT P10636 3/20 0.39
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CA1 P00915 1/20 0.39
CA9 Q16790 1/20 0.39
CCR2 P41597 1/20 0.38
TP53 P04637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3138003 0.78 MEN1 (0.48) LMNAGAAMEN1KMT2AL3MBTL1
SCHEMBL3132946 0.78 KDM4E (0.43) KDM4EGAAHPGDALDH1A1KMT2A
SCHEMBL3130252 0.78 CCR2 (0.45) LMNACCR2
SCHEMBL3132663 0.77 NSD2 (0.49) LMNAKDM4EGAAHPGDALDH1A1
SCHEMBL3133689 0.77 CCR2 (0.52) KDM4EGAAALDH1A1HSD17B10CCR2
SCHEMBL17774898 0.77 NAAA (0.42) KDM4EGAAALOX15HPGDMAPT
SCHEMBL3138266 0.77 ESRRG (0.43) KDM4EALDH1A1CA1CCR2SMN1; SMN2
SCHEMBL3131265 0.77 ALOX5 (0.41) CCR2
SCHEMBL3122618 0.74 CCR2 (0.52) ALDH1A1CCR2RAB9A
SCHEMBL6887760 0.73 NAAA (0.48) LMNAKDM4EHPGDALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807686-B2 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists N.V. ORGANON (NL) 2010-10-05 US disclosed
EP-1861380-B1 2-(4-OXO-4H-QUINAZOLIN-3-YL)ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS ORGANON NV (NL) 2010-07-07 EP disclosed
US-20080214553-A1 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists MERCK SHARP & DOHME B.V. (NL) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214553-A1 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists AVPR2, AVPR1A, AVPR1B LMNA 2726/4885KDM4E 2703/4885GAA 4446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.